Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China flag China · Delayed Price · Currency is CNY
17.78
-0.24 (-1.33%)
Sep 11, 2026, 3:00 PM CST

SHA:600645 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,3841,4231,5501,5381,5071,497
Other Revenue
14.2132.1135.8152.0747.837.94
1,3981,4551,5851,5901,5551,535
Revenue Growth
-6.77%-8.23%-0.27%2.24%1.27%16.41%
Cost of Revenue
419.35458.73497.75505.02510.29473.84
Gross Profit
978.6996.221,0881,0851,0451,061
Selling, General & Admin
635.71650.04695.33719.77723.4749.78
Research & Development
147.49149.01182.11184.49146.12133.85
Other Operating Expenses
17.9322.3419.3919.1917.5916.54
Operating Expenses
810.7843.04924.48946.57901.67937.05
Operating Income
167.9153.18163.2138.14142.93124.44
Interest Expense
-1.42-3.23-5.03-5.02-4.02-3.14
Interest & Investment Income
6.6617.924.429.5918.2316.21
Earnings From Equity Investments
-15.88-13.67-14.3-11.85-7.96-
Currency Exchange Gain (Loss)
3.814.59-3.21.51-2.370.1
Other Non Operating Income (Expenses)
9.520.1-3.221.03-2-1.49
EBT Excluding Unusual Items
170.59158.87161.84153.4144.82136.13
Impairment of Goodwill
------19.72
Gain (Loss) on Sale of Investments
10.525.76-30.03-36.09-0.7579.09
Gain (Loss) on Sale of Assets
8.296.411.33.672.030.51
Asset Writedown
-5.76-1.35-4.68-0.31-0.8-6.26
Other Unusual Items
3.64.767.5211.929.933.2
Pretax Income
187.24174.45135.95132.59155.21222.96
Income Tax Expense
76.670.9246.5934.0348.5371.75
Earnings From Continuing Operations
110.64103.5389.3598.55106.68151.21
Minority Interest in Earnings
6.4710.3117.96.34.11
Net Income
117.11113.83100.35106.45112.99155.32
Net Income to Common
117.11113.83100.35106.45112.99155.32
Net Income Growth
60.56%13.43%-5.73%-5.78%-27.26%-
Shares Outstanding (Basic)
468455456463471471
Shares Outstanding (Diluted)
468455456463471471
Shares Change
5.93%-0.18%-1.45%-1.69%0.02%0.17%
EPS (Basic)
0.250.250.220.230.240.33
EPS (Diluted)
0.250.250.220.230.240.33
EPS Growth
51.57%13.64%-4.35%-4.17%-27.27%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
278.33264.07217.87210.4162.7193.22
Free Cash Flow Per Share
0.590.580.480.460.350.41
Gross Margin
70.00%68.47%68.61%68.23%67.18%69.14%
Operating Margin
12.01%10.53%10.29%8.69%9.19%8.11%
Profit Margin
8.38%7.82%6.33%6.70%7.27%10.12%
Free Cash Flow Margin
19.91%18.15%13.74%13.23%10.46%12.58%
EBITDA
285.24250.27305.17281.74253.74227.35
EBITDA Margin
20.40%17.20%19.25%17.72%16.32%14.81%
D&A For EBITDA
117.3497.09141.97143.6110.81102.91
EBIT
167.9153.18163.2138.14142.93124.44
EBIT Margin
12.01%10.53%10.29%8.69%9.19%8.11%
Effective Tax Rate
40.91%40.65%34.27%25.67%31.26%32.18%
Revenue as Reported
738.581,4551,5851,5901,5551,535
Advertising Expenses
-26.5330.8632.9829.0232.43